Al Adel Fadwa, Shoughy Samir S, Tabbara Khalid F
Department of Ophthalmology, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
The Eye Center and The Eye Foundation for Research in Ophthalmology, King Saud University, Riyadh, Saudi Arabia.
Saudi J Ophthalmol. 2021 Feb 27;34(3):151-155. doi: 10.4103/1319-4534.310400. eCollection 2020 Jul-Sep.
To assess the ocular toxicity in patients on high doses of hydroxychloroquine (HCQ) per weight, as per the latest American Academy of Ophthalmology (AAO) screening guidelines for HCQ toxicity.
This is a multi-center study looking at consecutive patients attending the ophthalmology clinics at a tertiary hospital and a private clinic in Saudi Arabia. A data collection sheet was used to collect patient's information regarding the dose per body weight, duration of HCQ use and any risk factors associated with the use of the medication as per the latest AAO guidelines for HCQ screening. Ancillary testing including fundus photography, automated visual field (10-2) and spectral domain ocular coherence tomography were done. Further testing with fundus auto-fluorescence and multifocal ERG were done when needed. The presence or absence of toxicity was recorded.
A total of 63 patients were included in the study, 58 females and 5 males. The average patient age was 45 years (range 18-72). The mean dosage of HCQ was 3.9 mg/kg. Fourteen (22%) patients were on doses higher than 5 mg/kg. The duration of treatment ranged from 1-30 years (average 8.3). Thirty six (57%) patients were on the drug for more than 5 years. We found only one (1.58%) patient with HCQ toxic retinopathy over a mean of 8 years treatment period.
A significant number of our patients were found to be on doses of >5 mg/kg of HCQ, which may put them at a higher risk for retinal toxicity. Low dose HCQ such as 100 mg tablets should be made available to help physicians in adjusting the dose as per the latest reported guidelines by the AAO.
根据美国眼科学会(AAO)最新的羟氯喹(HCQ)毒性筛查指南,评估按体重服用高剂量HCQ患者的眼部毒性。
这是一项多中心研究,观察沙特阿拉伯一家三级医院和一家私人诊所眼科门诊的连续就诊患者。使用数据收集表,根据AAO最新的HCQ筛查指南,收集患者关于每体重剂量、HCQ使用时长以及与药物使用相关的任何风险因素的信息。进行了包括眼底照相、自动视野检查(10-2)和光谱域光学相干断层扫描在内的辅助检查。必要时进行了眼底自发荧光和多焦视网膜电图的进一步检查。记录毒性的有无。
共有63例患者纳入研究,58例女性,5例男性。患者平均年龄为45岁(范围18-72岁)。HCQ的平均剂量为3.9mg/kg。14例(22%)患者的剂量高于5mg/kg。治疗时长为1-30年(平均8.3年)。36例(57%)患者用药超过5年。在平均8年的治疗期内,我们仅发现1例(1.58%)患者患有HCQ毒性视网膜病变。
我们发现相当数量的患者服用的HCQ剂量>5mg/kg,这可能使他们面临更高的视网膜毒性风险。应提供如100mg片剂这样的低剂量HCQ,以帮助医生根据AAO最新报告的指南调整剂量。